Medikaloka Hermina Dirección

Dirección controles de criterios 2/4

El CEO de Medikaloka Hermina's es H. Hasmoro, nombrado en Jan 1991, tiene una permanencia de 33.25 años. posee directamente un 4.74% de las acciones de la empresa, con un valor de IDR789.13B. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 6.3 años, respectivamente.

Información clave

H. Hasmoro

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	33.7yrs
Participación del CEO	4.8%
Permanencia media de la dirección	4yrs
Promedio de permanencia en la Junta Directiva	6.7yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

H. Hasmoro (80 yo)

33.7yrs

Permanencia

Dr. H. Hasmoro, Sp An, KIC, MHA, MM, has been President Director of PT Medikaloka Hermina Tbk since 1991. Previously, Dr. Hasmoro served as Member of Presidential Specialist Team from 1987 to 2000.He join...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
H. Hasmoro	President Director	33.7yrs	sin datos	4.84% IDR 937.2b
Yulisar Khiat	MD of Finance & Strategic Development and Director	less than a year	sin datos	12.39% IDR 2.4t
Tan Gunadi	MD of Operational & General Affairs and Director	less than a year	sin datos	sin datos
Binsar Simorangkir	MD of Medical and Compliance & Director	no data	sin datos	6.08% IDR 1.2t
Arie Wahyudi	Head of Licensing & Legal	no data	sin datos	sin datos
Muyi Hapsari	Head of Marketing	no data	sin datos	sin datos
Susi Setiawaty	MD of Human Capital	4yrs	sin datos	sin datos
Meijani Wibowo	Commissioner	no data	sin datos	2.21% IDR 428.7b
Hastiyudo Wibowo	Business Development	no data	sin datos	sin datos
Chatarina Sri Marsiyo	Head of Internal Audit	4yrs	sin datos	sin datos
Yuyun Gunaedi	Information Technology	no data	sin datos	sin datos

4.0yrs

Permanencia media

65.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HEAL se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
H. Hasmoro	President Director	33.7yrs	sin datos	4.84% IDR 937.2b
Yulisar Khiat	MD of Finance & Strategic Development and Director	27.7yrs	sin datos	12.39% IDR 2.4t
Tan Gunadi	MD of Operational & General Affairs and Director	less than a year	sin datos	sin datos
Binsar Simorangkir	MD of Medical and Compliance & Director	26.7yrs	sin datos	6.08% IDR 1.2t
Susi Setiawaty	MD of Human Capital	less than a year	sin datos	sin datos
Meijani Wibowo	Commissioner	2.7yrs	sin datos	2.21% IDR 428.7b
Amit Varma	Independent Commissioner	4.7yrs	sin datos	sin datos
Alexander Rusli	Independent Commissioner	6.7yrs	sin datos	sin datos
Darwin Noerhadi	Commissioner	7.7yrs	sin datos	sin datos
Husen Sutakaria	Vice President Commissioner	6.7yrs	sin datos	2.85% IDR 550.8b
Paulus Gunawan	President Commissioner	7.7yrs	sin datos	sin datos
. Heridadi	Independent Commissioner	6.7yrs	sin datos	sin datos

6.7yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de HEAL se considera experimentada (6.3 años de antigüedad promedio).

Medikaloka Hermina Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Key Executive recently bought Rp109b worth of stock

President Director recently bought Rp5.0b worth of stock

President Director recently bought Rp8.3b worth of stock

President Director recently bought Rp308m worth of stock

Key Executive recently bought Rp687m worth of stock

Key Executive recently bought Rp12b worth of stock

Recent updates

Key Executive recently bought Rp109b worth of stock

President Director recently bought Rp5.0b worth of stock

Second quarter 2024 earnings released: EPS: Rp10.25 (vs Rp6.45 in 2Q 2023)

President Director recently bought Rp8.3b worth of stock

Consensus EPS estimates increase by 13%

Investor sentiment improves as stock rises 17%

Now 20% overvalued

First quarter 2024 earnings released: EPS: Rp12.96 (vs Rp7.52 in 1Q 2023)

Full year 2023 earnings released: EPS: Rp30.16 (vs Rp20.64 in FY 2022)

New minor risk - Shareholder dilution

President Director recently bought Rp308m worth of stock

Key Executive recently bought Rp687m worth of stock

Third quarter 2023 earnings released: EPS: Rp10.12 (vs Rp5.61 in 3Q 2022)

Key Executive recently bought Rp12b worth of stock

Second quarter 2023 earnings released: EPS: Rp6.45 (vs Rp3.68 in 2Q 2022)

Price target increased to Rp2,170

Less than half of directors are independent

Consensus EPS estimates fall by 17%

PT Medikaloka Hermina Tbk Ordinary Shares to Be Deleted from OTC Equity

First quarter 2022 earnings: Revenues in line with analyst expectations

Price target increased to Rp1,427

Consensus EPS estimates fall by 15%

Less than half of directors are independent

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

PT Medikaloka Hermina Tbk (IDX:HEAL) announces an Equity Buyback for 80,000,000 shares, for IDR 116,000 million.

Third quarter 2021 earnings released: EPS Rp15.57 (vs Rp10.64 in 3Q 2020)

Price target increased to Rp1,255

Second quarter 2021 earnings released

Consensus EPS estimates increase to Rp50.58

Investor sentiment improved over the past week

Consensus EPS estimates increase to Rp222

Price target increased to Rp5,756

First quarter 2021 earnings released: EPS Rp95.79 (vs Rp24.16 in 1Q 2020)

Price target increased to Rp5,150

Consensus EPS estimates increase to Rp173

Price target increased to Rp4,959

Consensus EPS estimates increase to Rp160

New 90-day high: Rp4,200

New 90-day high: Rp4,000

New 90-day high: Rp3,930

Analysts update estimates

Price target raised to Rp4,368

New 90-day high: Rp3,450

Third quarter 2020 earnings released: EPS Rp53.13

First half earnings released

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad